Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine

被引：29

作者：

Talbot, H. Keipp ^{[1
]}

Keitel, Wendy ^{[2
]}

Cate, Thomas R. ^{[2
]}

Treanor, John ^{[3
]}

Campbell, James ^{[4
]}

Bradye, Rebecca C. ^{[5
]}

Graham, Irene ^{[6
]}

Dekker, Cornelia L. ^{[7
]}

Ho, Dora ^{[7
]}

Winokur, Patricia ^{[8
,9
]}

Walter, Emmanuel ^{[10
]}

Bennet, Jillian ^{[11
]}

Formica, Neil ^{[11
]}

Hartel, Gunter ^{[11
]}

Skeljo, Maryanne ^{[11
]}

Edwards, Kathryn M. ^{[1
]}

机构：

[1] Vanderbilt Univ, Sch Med & Pediat, Med Ctr, Nashville, TN 37232 USA

[2] Baylor Coll Med, Houston, TX 77030 USA

[3] Univ Rochester, Rochester, NY 14642 USA

[4] Univ Maryland, Sch Med, Baltimore, MD 21201 USA

[5] Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA

[6] St Louis Univ, Hlth Sci Ctr, St Louis, MO 63110 USA

[7] Stanford Univ, Sch Med, Stanford, CA 94305 USA

[8] Univ Iowa, Iowa City, IA USA

[9] Iowa City VAMC, Iowa City, IA USA

[10] Duke Univ, Durham, NC USA

[11] CSL Ltd, Parkville, VIC 3052, Australia

来源：

VACCINE | 2008年 / 26卷 / 32期

关键词：

influenza; vaccine; immunogenicity;

D O I：

10.1016/j.vaccine.2008.05.024

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

To augment the available influenza vaccine supply, a phase III study was conducted to evaluate the immunogenicity, safety, and consistency of a new trivalent inactivated influenza vaccine manufactured by CSL Limited. Healthy adults (ages 18-64) were randomized to receive either a single dose of TIV from multi-dose vials with thimerosal, TIV from pre-filled syringes without thimerosal, or placebo. Of the TIV recipients, 97.8% achieved a post-vaccination titer >= 40 against H1N1, 99.9% against H3N2 component, and 94.2% against influenza B. Few local or systemic adverse events were noted after vaccination with either TIV presentation. TIV was well tolerated and immunogenic. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：4057 / 4061

页数：5

共 50 条

[1] Immunogenicity and safety of a trivalent inactivated influenza vaccine
Fadlyana, Eddy
Rusmili, Kusnandi
Bachtiar, Novilia Sjafri
Gunadi, Rachmat
Sukandar, Hadyana
[J]. PAEDIATRICA INDONESIANA, 2011, 51 (01) : 22 - 28
[2] Safety and immunogenicity of trivalent inactivated influenza vaccine in infants
Halasa, Natasha B.
Gerber, Michael A.
Chen, Qingxia
Wright, Peter F.
Edwards, Kathryn M.
[J]. JOURNAL OF INFECTIOUS DISEASES, 2008, 197 (10): : 1448 - 1454
[3] Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China
Mo, Zhaojun
Nong, Yi
Liu, Shuzhen
Shao, Ming
Liao, Xueyan
Go, Kerry
Lavis, Nathalie
[J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (06) : 1272 - 1278
[4] Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults
Greenberg, David P.
Robertson, Corwin A.
Noss, Michael J.
Blatter, Mark M.
Biedenbender, Rex
Decker, Michael D.
[J]. VACCINE, 2013, 31 (05) : 770 - 776
[5] Immunogenicity, safety and tolerability of inactivated trivalent influenza vaccine in overweight and obese children
Esposito, Susanna
Giavoli, Claudia
Trombetta, Claudia
Bianchini, Sonia
Montinaro, Valentina
Spada, Anna
Montomoli, Emanuele
Principi, Nicola
[J]. VACCINE, 2016, 34 (01) : 56 - 60
[6] Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection: an overview of systematic reviews
Carregaro, Rodrigo Luiz
Roscani, Alessandra N. C. P.
Raimundo, Augusto Cesar Sousa
Ferreira, Larissa
Vanni, Tazio
Salomao, Maria da Graca
Probst, Livia Fernandes
Viscondi, Juliana Yukari K.
[J]. BMC INFECTIOUS DISEASES, 2023, 23 (01)
[7] Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection: an overview of systematic reviews
Rodrigo Luiz Carregaro
Alessandra N. C. P. Roscani
Augusto Cesar Sousa Raimundo
Larissa Ferreira
Tazio Vanni
Maria da Graça Salomão
Livia Fernandes Probst
Juliana Yukari K. Viscondi
[J]. BMC Infectious Diseases, 23
[8] Immunogenicity and safety of influenza trivalent inactivated vaccine in hemodialysis patients and renal transplant recipients
Scharpe, Johan
Evenepoel, Pieter
Claes, Kathleen
Kuypers, Dirk
Osterhaus, Albert D.
Vanwalleghem, Johan
Vanrenterghem, Yves
Peetermans, Willy E.
[J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 : 228 - 228
[9] Safety and immunogenicity of a Proteosome™-trivalent inactivated influenza vaccine, given nasally to healthy adults
Langley, JM
Halperin, SA
McNeil, S
Smith, B
Jones, T
Burt, D
Mallett, CP
Lowell, GH
Fries, L
[J]. VACCINE, 2006, 24 (10) : 1601 - 1608
[10] Immunogenicity and Safety of an Inactivated Trivalent Split Influenza Virus Vaccine in Young Children with Recurrent Wheezing
Bae, E. Young
Choi, Ui Yoon
Kwon, Hyo Jin
Jeong, Dae Chul
Rhim, Jung Woo
Ma, Sang Hyuk
Lee, Kyung Il
Kang, Jin Han
[J]. CLINICAL AND VACCINE IMMUNOLOGY, 2013, 20 (06) : 811 - 817

← 1 2 3 4 5 →